Chevy Chase Trust Holdings LLC Has $123.03 Million Stake in Abbott Laboratories $ABT

Chevy Chase Trust Holdings LLC decreased its position in Abbott Laboratories (NYSE:ABT) by 3.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 918,563 shares of the healthcare product maker’s stock after selling 31,238 shares during the quarter. Chevy Chase Trust Holdings LLC owned about 0.05% of Abbott Laboratories worth $123,032,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in ABT. Norges Bank bought a new stake in Abbott Laboratories in the second quarter worth approximately $3,026,180,000. Laurel Wealth Advisors LLC raised its holdings in shares of Abbott Laboratories by 13,347.0% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock valued at $823,804,000 after purchasing an additional 6,011,891 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after purchasing an additional 4,713,135 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Abbott Laboratories by 1.8% in the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after purchasing an additional 2,977,715 shares in the last quarter. Finally, First Trust Advisors LP increased its position in Abbott Laboratories by 180.7% during the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock worth $416,659,000 after buying an additional 1,972,097 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABT has been the topic of several recent research reports. Leerink Partners cut their target price on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a report on Friday, January 30th. The Goldman Sachs Group lowered their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Argus cut their price objective on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Royal Bank Of Canada reduced their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Finally, Sanford C. Bernstein lowered their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $136.16.

Abbott Laboratories Trading Down 0.1%

Shares of ABT stock opened at $107.99 on Friday. The firm has a market capitalization of $187.66 billion, a P/E ratio of 29.03, a price-to-earnings-growth ratio of 1.72 and a beta of 0.74. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $139.06. The firm’s fifty day simple moving average is $114.58 and its 200 day simple moving average is $123.86. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business’s revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Insider Activity

In other news, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were purchased at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the purchase, the director directly owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This represents a 0.60% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.